李晶晶, 祖磊, 薛鹏程. TR3受体激动剂6-mercaptopurine对糖尿病ApoE-/-小鼠NF-κB p65/CylinD1通路影响及其与抗动脉硬化关系[J]. 蚌埠医科大学学报, 2019, 44(9): 1137-1142. DOI: 10.13898/j.cnki.issn.1000-2200.2019.09.001
    引用本文: 李晶晶, 祖磊, 薛鹏程. TR3受体激动剂6-mercaptopurine对糖尿病ApoE-/-小鼠NF-κB p65/CylinD1通路影响及其与抗动脉硬化关系[J]. 蚌埠医科大学学报, 2019, 44(9): 1137-1142. DOI: 10.13898/j.cnki.issn.1000-2200.2019.09.001
    LI Jing-jing, ZU Lei, XUE Peng-cheng. Effect of TR3 receptor agonist 6-mercaptopurine on NF-κB p65/CylinD1 pathway in diabetic ApoE-/- mice, and its relationship with anti-arteriosclerosis[J]. Journal of Bengbu Medical University, 2019, 44(9): 1137-1142. DOI: 10.13898/j.cnki.issn.1000-2200.2019.09.001
    Citation: LI Jing-jing, ZU Lei, XUE Peng-cheng. Effect of TR3 receptor agonist 6-mercaptopurine on NF-κB p65/CylinD1 pathway in diabetic ApoE-/- mice, and its relationship with anti-arteriosclerosis[J]. Journal of Bengbu Medical University, 2019, 44(9): 1137-1142. DOI: 10.13898/j.cnki.issn.1000-2200.2019.09.001

    TR3受体激动剂6-mercaptopurine对糖尿病ApoE-/-小鼠NF-κB p65/CylinD1通路影响及其与抗动脉硬化关系

    Effect of TR3 receptor agonist 6-mercaptopurine on NF-κB p65/CylinD1 pathway in diabetic ApoE-/- mice, and its relationship with anti-arteriosclerosis

    • 摘要:
      目的观察TR3受体激动剂(6-mercaptopurine,6-MP)对链脲佐菌素(streptozotocin,STZ)诱导的载脂蛋白E(apolipoprotein E,ApoE-/-)敲除糖尿病小鼠糖脂代谢及NF-κB p65/CylinD1通路的影响及其与抗动脉硬化的关系,探讨TR3受体在改善糖尿病动脉粥样硬化可能机制。
      方法40只雄性ApoE-/-小鼠随机分为4组:ApoE-/-组、STZ-ApoE-/-组、STZ-ApoE-/-+6-MP5(5 mg·kg-1·d-1)组、STZ-ApoE-/-+6-MP10(10 mg·kg-1·d-1)组,每组10只;6-MP腹腔注射法给药,每天1次,连续8周;STZ 60 mg/kg腹腔注射ApoE-/-小鼠建立糖尿病动脉粥样硬化模型,血糖试纸法测血糖水平;酶法或匀相法测血脂水平;蛋白免疫印迹试验(Western-blotting)测胸主动脉组织NF-κB p65/CylinD1蛋白水平;油红O染色观察胸主动脉内膜动脉脂质沉积;HE染色测胸主动脉内膜粥样斑块面积。
      结果与ApoE-/-组相比,STZ-ApoE-/-组血糖及血清TG、TCHO、LDL-C均显著增高(P < 0.05);TR3受体激动剂6-MP呈剂量依赖性降低糖尿病ApoE-/-小鼠血糖、血脂水平,与STZ-ApoE-/-组相比,STZ-ApoE-/-+6-MP5组血糖、TG、LDL-C、TC均显著降低(P < 0.05),与ApoE-/-组相比,STZ-ApoE-/-组胸主动脉NF-κBp65、CylinD1蛋白表达水平均显著增加(P < 0.05);6-MP呈剂量依赖性降低糖尿病ApoE-/-小鼠胸主动脉NF-κBp65/CylinD1蛋白表达,STZ-ApoE-/-+6-MP5组NF-κB p65/CylinD1蛋白表达水平均明显低于STZ-ApoE-/-组(P < 0.05);STZ-ApoE-/-+6-MP10组与STZ-ApoE-/-+6-MP5组之间胸主动脉NF-κB p65/CylinD1蛋白表达水平差异均有统计学意义(P < 0.05)。油红O染色显示:TR3受体激动剂6-MP可呈剂量依赖性抑制STZ-ApoE-/-小鼠胸主动脉内膜脂质沉积;HE染色显示:TR3受体激动剂6-MP可呈剂量依赖性降低STZ-ApoE-/-小鼠胸主动脉内膜斑块面积,减少斑块内部有空洞(脂质)形成,抑制斑块周围组织及斑块基底部平滑肌层增生,与STZ-ApoE-/-组相比,STZ-ApoE-/-+6-MP5组胸主动脉内膜斑块面积明显减小(P < 0.05),STZ-ApoE-/-6-MP10组斑块面积进一步减小(P < 0.01)。
      结论TR3激动剂6-MP可明显降低糖尿病ApoE-/-小鼠动脉粥样硬化的形成,其机制可能与其改善糖脂代谢,抑制NF-κB p65/CylinD1信号通路有关。

       

      Abstract:
      ObjectiveTo observe the effects of TR3 receptor agonist 6-mercaptopurine(6-MP) on the glucose and lipid metabolism and NF-κB p65/CylinD1 pathway in streptozotocin (STZ)-induced diabetic apolipoprotein E knockout(ApoE-/-) mice, and explore the possible mechanism of TR3 receptors in improving diabetic atherosclerosis.
      MethodsForty ApoE-/- mice were randomly divided into the ApoE-/- group, STZ-ApoE-/- group, STZ-ApoE-/- +6-MP5(5 mg·kg-1·d-1) and STZ-ApoE-/- +6-MP10(10 mg·kg-1·d-1) group(10 rats each group).The 6-MP intraperitoneal injection was implemented, once a day, for 8 weeks.The diabetic animal model was established using intraperitoneal injection of STZ.The levels of blood glucose and blood lipid were determined using the blood glucose test strip and the enzymic method or selective homogeneous method, respectively.The Western-blotting was used to detect the protein levels of NF-κB p65/CylinD1 in thoracic aorta tissue, the lipid deposition in the thoracic aortic intima was observed by oil red O staining, and the patch area in the thoracic aorta was measured using HE staining.
      ResultsCompared with the ApoE-/- mice group, the levels of blood glucose, triglyceride(TG), total cholesterol(TCHO) and low-density lipoprotein-cholesterol(LDL-C) significantly increased in STZ-ApoE-/- group(P < 0.05), and the level of TR3 receptor agonist 6-MP decreased the levels of plasma glucose and lipid with dose-dependently.Comapred the STZ-ApoE-/- group, the levels of the blood glucose and TG, LDL-A and TC significantly decreased in the STZ-ApoE-/- +6-MP5 group(P < 0.05).Compared with the ApoE-/- group, the levels of NF-κB p65 and CylinD1 remarkably increased in the STZ-ApoE-/- group(P < 0.05).The 6-MP reduced the expression level of NF-κB p65/CylinD1 protein in thoracic aorta of diabetic ApoE-/- mice in a dose-dependent manner, and the protein level of NF-κB p65/CylinD1 in STZ-ApoE-/- +6-MP5 group were significantly lower than that in STZ-ApoE-/- group(P < 0.05).The differences of the levels of NF-κB p65/CylinD1 in thoracic aorta between STZ-ApoE-/- +6-MP10 group and STZ-ApoE-/- +6-MP5 group were statistically significnat(P < 0.05).The results of oil red O staining showed that 6-MP inhibited the intima lipid deposition in the thoracic aorta of STZ-ApoE-/- mice in a dose-dependent manner.The results of HE staining showed that 6-MP reduced the area of intima plaque and formation of vacuoles(lipids) inside plaque, and inhibited the proliferation of smooth muscle layer around plaque and plaque base in the thoracic aorta of STZ-ApoE-/- mice in a dose-dependent manner.Compared with the STZ-ApoE-/- group, the plaque area in the STZ-ApoE-/- +6-MP5 group significantly reduced(P < 0.05), and further reduced in the STZ-ApoE-/- 6-MP10 group(P < 0.01).
      ConclusionsThe TR3 receptor agonist 6-MP can significantly decrease the formation of atherosclerosis in diabetic ApoE-/- mice, which may be related to the improvement of glycolipid metabolism and inhibition of NF-κB p65/CylinD1 signaling pathway.

       

    /

    返回文章
    返回